tirzepatide surpass SURPASS-CVOT trial: For patients with high-risk type 2 diabetes, the effect of tirzepatide, a dual agonist of the GLP-1 and glucose-dependent insulinotropic polypeptide receptors, on cardiovascular outcomes is uncertain. Research is summarized Effect of tirzepatide versus insulin

On a 100-unit syringe, 50 units is 0.5 mL

Tap and distilled water are not sterile

If you have a significant amount of weight to lose, some procedures and medications can help you lose weight and keep it off, but there are benefits and drawbacks to consider with each

Already have a package

This industry-sponsored trial analyzed semaglutide's potential in a large cohort of around 18 000 patients

What to record: Number of bathroom visits per day (daytime and nighttime separately) Approximate volume (small, moderate, large) Any pain, burning, urgency, or incontinence Urine color throughout the day Total daily fluid intake (type and amount) Current tirzepatide dose and how long at this dose All other medications and supplements Blood sugar readings if applicable This data allows your provider to quickly distinguish between harmless metabolic adjustment and something requiring investigation